Tel Aviv , Oct. 15, 2021 (GLOBE NEWSWIRE) -- Cellect Biotechnology Ltd. (NASDAQ: “APOP”) (the “Company”), announced today the record date and...
Tel Aviv, Sept. 27, 2021 (GLOBE NEWSWIRE) -- Cellect Biotechnology Ltd. (NASDAQ: "APOP"), announced shareholders voted to approve the previously announced strategic merger agreement with privately-held...
Recruitment of Patient Provides Momentum to Commence Funding for the Technology under US Entity EnCellX
Strategic Merger Transaction Remains on Track to Close During the 2021 Third Quarter
Special General Meeting of Shareholders Scheduled for September 19, 2021
Transaction Expected to Close in the 2021 Third Quarter
Results Support Ongoing Clinical Development of ApoGraft in U.S.
TEL AVIV, Israel, March 29, 2021 (GLOBE NEWSWIRE) -- Cellect Biotechnology Ltd. (NASDAQ: “APOP”), a developer of innovative technology that enables the functional selection of stem cells, today reported...
Up to $25 million of funding at $75 million pre-money valuation to be available to the combined company concurrently with the merger
Promising Progress on Clinical D evelopment Progress , Collaboration s and Partnering